论文部分内容阅读
目的:HBV感染患者血清中HBV相关miRNAS的表达水平会出现变化,分析乙肝病毒特异性miRNAs在乙肝肝癌(hepato-cellular carcinoma,HCC)患者血清中的表达水平与术后肿瘤复发的关系。方法:采用实时荧光定量RT-PCR(Real-time RT-PCR)检测38例乙肝肝癌患者手术前后血清乙肝病毒特异性miRNAs(miR-122和miR-22)的表达。分析血清乙肝病毒特异性miRNAs的表达水平与肝癌切除术后的预后与复发的关系。结果:乙肝肝癌患者血清miR-122和miR-22明显高于良性肝病和正常对照组(P<0.01)。手术前后血清miR-122和miR-22的表达差异显著(P<0.01)。乙肝肝癌患者血清miR-122和miR-22表达的高低与HBVDNA、肝硬化、AFP、肿瘤大小、病理分化、TNM分级有关(P<0.05)。血清miR-122和miR-22低表达组的复发转移率显著低于高表达组(P<0.01)。结论:miR-122和miR-22在乙肝肝癌患者血清中表达上调与肝癌复发转移率高和预后差密切相关,提示其可能是一个潜在的HCC预后分子标志物。
OBJECTIVE: The expression of HBV-related miRNAs in serum of patients with HBV infection will change, and the relationship between the expression of hepatitis B virus-specific miRNAs in serum of patients with hepatocellular carcinoma (HCC) and tumor recurrence after operation is analyzed. Methods: Real-time RT-PCR was used to detect the expression of serum HBV-specific miRNAs (miR-122 and miR-22) in 38 patients with hepatocellular carcinoma before and after operation. To analyze the relationship between the expression of serum HBV-specific miRNAs and prognosis and recurrence after resection of liver cancer. Results: The serum levels of miR-122 and miR-22 in patients with hepatocellular carcinoma were significantly higher than those in benign liver disease and normal controls (P <0.01). The levels of serum miR-122 and miR-22 were significantly different before and after surgery (P <0.01). The levels of miR-122 and miR-22 in patients with hepatocellular carcinoma were correlated with HBVDNA, cirrhosis, AFP, tumor size, pathological differentiation and TNM classification (P <0.05). The recurrence and metastasis rates of serum miR-122 and miR-22 low expression group were significantly lower than those of high expression group (P <0.01). Conclusion: The upregulation of miR-122 and miR-22 in the serum of patients with hepatocellular carcinoma is closely related to the high recurrence rate and poor prognosis of hepatocellular carcinoma, suggesting that it may be a potential molecular marker of HCC prognosis.